Kowa Company, Ltd.

Quick facts

Phase 3 pipeline

• K-924 HD · Cardiovascular
  K-924 HD is a selective aldosterone antagonist that blocks mineralocorticoid receptor signaling to reduce sodium retention and blood pressure.
• K-924 LD · Neurology
  K-924 LD is a long-acting dopamine D2/D3 receptor agonist designed to provide sustained dopaminergic activity for extended treatment intervals.
• NIK-333(peretinoin) · Oncology
  NIK-333 (peretinoin) is a synthetic retinoid that acts as a retinoic acid receptor agonist.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kowa Company, Ltd. portfolio CI brief
• Kowa Company, Ltd. pipeline updates RSS